Web Date: October 16, 2017
Roche, Warp Drive form antibiotics pact
Warp Drive Bio has secured another lucrative partnership for its genome mining drug discovery platform. Roche will pay up to $87 million in preclinical milestones and fees as part of a pact to explore new classes of natural products targeting gram-negative bacteria.
Researchers have long relied on molecules made by soil bacteria as the starting point for antibiotics development. But despite decades of trying, in the lab they can only coax bacteria into making a . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society